PetDx is a molecular diagnostics company that utilizes advanced genomic sequencing techniques to detect cancer in pets at an early stage. By providing accurate and timely diagnoses, PetDx enables veterinarians to implement targeted treatment plans, improving outcomes for affected animals.
Funding
$71.8M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
LAFounders
Product
Problem
Pet cancer is a leading cause of death in companion animals, and early detection is critical for improving treatment outcomes. Traditional diagnostic methods often fail to identify cancer until it has progressed to an advanced stage, limiting therapeutic options.
Solution
PetDx offers a liquid biopsy test that leverages next-generation sequencing (NGS) to detect cancer-associated genomic alterations in canine blood samples. The non-invasive test analyzes circulating tumor DNA (ctDNA) to identify multiple types of cancer at an earlier stage than traditional methods. By providing veterinarians with comprehensive genomic insights, PetDx enables more informed treatment decisions and personalized care plans for dogs.
Target Audience
The primary customers are veterinarians who seek advanced diagnostic tools for early cancer detection in canine patients.
Features
- Utilizes next-generation sequencing (NGS) technology for comprehensive genomic analysis
- Detects circulating tumor DNA (ctDNA) in canine blood samples
- Identifies multiple types of cancer at an early stage
- Provides veterinarians with actionable genomic insights
- Non-invasive liquid biopsy approach